upgrad ow establish pt
becton share under-perform broader group year-to-d share spike
all-tim high late januari mix earn market volatil led share
pull back two quarter bard acquisit see clear path becton
exceed top bottom-lin expect exce
bard synergi target time continu benefit neutral price
upsid opportun aggress price captur leverag broad
portfolio gener multipl small win reliabl strategi
depend one two blockbust launch sustain organ sale
growth minimum low-double-digit ep growth arguabl given
forese futur sustain convers believ becton deserv
premium multipl even factor leverag upgrad
recommend becton neutral overweight establish dec-
price target blend ep ebitda
see upsid street fiscal top bottom-lin estim set
beat rais scenario well start top-lin manag
organ growth guidanc current fall in-lin compani
organ growth one hand compani longer see
benefit flu tailwind howev off-set
step-up medic vs pro-forma organ
back-half acceler pharmaceut system easi comp continu
mid-singl digit growth balanc busi ex-dispens also model
continu mid-singl digit growth lifesci continu
strength intervent busi result pro-forma
growth exclud headwind us dispens
hurrican conserv bar give becton room outperform
see clear path underli oper margin expans
plu anoth back half year see clear
benefit two full quarter bard portfolio legaci
busi run om close ex-gor compar legaci becton
low-to-mid importantli also coupl benefit
anniversari us dispens account chang headwind
om ep om headwind ep
coupl earli round synergi captur model om
expans year get us cash ep
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
deliv bard deal key becton stori go forward
remain highli confid manag abil execut key aspect
integr instil becton cultur categori leadership bard
see strategi core compet becton help compani
build invalu partner one-stop-shop hospit system
work look revenu synergi opportun believ near-term
focu fall china given bard presenc tier hospit becton
presenc tier expand bard limit presenc ou market outsid
china japan manag specif call opportun apac
emea latam opportun drive cross-sel account us
told manag expect bard synergi start time
exceed peak carefus sale synergi see upsid number
dont expect target rais next year notic synergi benefit
top-lin expect begin increment invest revenu
synergi expect begin year spend expect area
chloraprep europ unif product line picc port
cathet margin side manag clear line-of-sight pre-tax
target expect target rais higher integr progress
like ie
least quarter post-clos convers
tax synergi repres upsid bard accret target street
dont includ estim tax synergi could repres upsid current
guidanc inher complex reconcil tax coupl recent overhaul
us tax law led manag keep forecast howev
manag recogn tax benefit cfn acquisit believ
like gener tax save bcr though magnitud impact
difficult forecast
price also area potenti upsid becton one med-tech
compani price isnt annual headwind stem compani
domin share posit mani market particip compani
repres major player core market syring tool pump
blood collect name go forward howev manag continu
expect similar price dynam baselin assumpt actual ytd
gain certain market off-set price concess other
gain like stem mix benefit rather price
possibl aggress price take futur manag caution
bake street estim time
two product line current benefit posit price
vacutain blood collect busi becton play catch
follow sever year hasnt taken price hypoderm needl
busi cardin health suppli busi struggl product becton
run manufactur capac suppli market even cardin
product come back becton think itll abl maintain much
look toward product side pyxi es still earli product cycl
one hand remain room continu market penetr hardwar side
becton convert roughli market pyxi es howev given
devic year instal cycl shift toward subscript model
recent account chang strategi focus monet
increment opportun softwar informat sale rather up-front
capit sale user util devic exist featur set
becton signific opportun leverag becton interconnect system
presenc hospit drive adopt softwar compani
recent launch healthsight platform becton medic manag
deliveri product becom interconnect particularli informat
overlay much difficult competitor compet vs complet
diabet franchis remain underappreci opportun multipl
launch set back half start compani bd flowsmart
infus set clinic trial expect begin later year follow product
redesign submiss follow prior version medtron
like run trial afterward put devic track late
launch date patch pump side compani basal-bolu pump
diabet also remain track launch like compani
pre-submiss meet come fda manag wasnt expect
showcas devic ada week note didnt expect pump
reveal medic confer
back new product wouldnt surpris see growth
segment tick upward high-single-digit rang us start
versu mid-singl digit current see flowsmart differenti product
demonstr efficaci type patch pump potenti
major growth catalyst becton abl deliv product featur
abl profit consist manufactur give becton
benefit doubt given core compet bulk manufactur ie test tube
look smaller notabl opportun would highlight
barricor expect return us market late earli
becton domin player vacutain market share grow
vs market could busi matur given price
premium barricor roughli vs hypoderm needl franchis
compani continu take share suppli busi
immunotherapi cancer becton leverag exist flow cytometri platform
upcom therapeut cell sorter posit major player could
new blockbust market
final worth address concern around compani debt load
littl long-term debt balanc sheet becton sit
gross debt ratio use rough pro-forma ebitda estim
clearli limit compani strateg option near term also believ becton
one compani best posit handl larg debt load cash
flow gener standpoint last three year becton maintain averag
convers ratio adjust net incom well peer averag
rang expect becton aggress leverag capabl pay
debt model point toward gross debt/ebitda fall
given strength becton outlook next year believ becton
deserv trade premium med-tech peer top-lin outlook point
toward sustain growth forese futur in-lin large-cap peer
compani ep compound-annual-growth-rate put class
premium name like coupl first-in-class
gener upsid bard integr stori assign becton overweight
rate establish decemb price target ep
ev/ebitda
invest thesi valuat risk
becton share under-perform broader group year-to-d share spike
all-tim high late januari mix earn market volatil led
share pull back investor remain wari name compani work
digest bard view notabl bullish see clear path
manag beat meet expect deliv current bard
synergi target rais line continu benefit neutral price
upsid opportun aggress price captur leverag
broad portfolio gener multipl small win reliabl strategi
depend one two blockbust launch clear path sustain mid-
single-digit organ growth minimum low-double-digit growth arguabl given
forese futur highest convers ratio coverag
believ becton deserv premium multipl even factor leverag
price target valu becton equal basi
ep ev/ebitda put modest premium
large-cap peer trade result believ premium justifi
given becton sustain organ top-lin par peer
ep compound-annual-growth-rate peer coupl first-in-class gener
risk rate price
downsid risk includ failur difficulti integr bard transact
macro pressur key end market signific strengthen dollar
becton dickinson co summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end sep o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
